Ypsomed Holding AG - Annual Report 2022/ 23
Printed Matter
myclimate.org/01-23-392491
Ypsomed Holding AG
Annual Report 2022/23
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with more than 35 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies.
Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs over 2 000 employees.
Table of content | 5 |
Table of content
- Key figures
-
Letter to shareholders
12 Engagement
14 Innovation & Digital Health
16 Ongoing development and digitisation
18 mylife Loop is a game changer for people with diabetes 20 We need to manage our growth in a responsible manner
22 Access & Expansion
24 Access to easy and high-qualityself-medication 26 New options for injecting drugs with large volumes 28 Treating obesity as a chronic disease
30 Responsibility & Engagement
32 On course in sustainability
40 Towards net zero emissions with sustainable plastics
42 Platforms & Operational Excellence
44 Increasing availability and expanding cost leadership
46 Energy generation and energy efficiency at the Schwerin site (DE) 48 Groundbreaking in China
50 Financial report 52 Profitable growth
54 Consolidated income statement 55 Consolidated balance sheet
56 Consolidated statement of cash flows
57 Consolidated statement of changes in equity 58 Basis for the consolidated fiinancial statements 64 Alternative Performance Measures
65 Notes to the consolidated financial statements 87 Statutory closing of Ypsomed Holding AG 97 Multi-year overview
98 Corporate Governance 102 Capital structure 104 Shareholder structure 105 Board of Directors 113 Executive Board
117 Remuneration, participations and loans 117 Shareholders' rights of participation
118 Change of control and blocking mechanisms 118 Auditors
119 Information policy
120 Remuneration Report
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ypsomed Holding AG published this content on 24 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2023 14:06:02 UTC.